{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:01:32Z","timestamp":1779897692897,"version":"3.53.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":117,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Medical Faculty of the University of Bonn, Germany","award":["2024-1A-03"],"award-info":[{"award-number":["2024-1A-03"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The optimal salvage therapy for recurrent MGMT-methylated glioblastoma (GBM), IDH wildtype, remains undefined. While lomustine is often used in clinical trials and considered standard-of-care, cumulative toxicity precludes its use in patients previously treated with lomustine\/temozolomide. The role of temozolomide rechallenge in this setting is unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This monocentric retrospective study included 70 patients with MGMT-methylated GBM, IDH wildtype, who received lomustine\/temozolomide as first-line therapy. Descriptive data on second-line therapies were collected, and therapy responses were assessed. Survival outcomes were evaluated using Kaplan-Meier analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 55 patients with documented tumor progression, 40 patients received second-line therapy. The most frequently used systemic therapy was temozolomide (n\u2005=\u200533, 79% of patients with second-line therapy), with a median number of 6 cycles and hematotoxicity grade 3 or 4 observed in\u2005&amp;lt;20% of patients. Among patients receiving temozolomide only, stable disease or partial response was achieved in 53.3%, with a progression-free survival rate at 6 months after first recurrence of 50% and a 1-year OS rate of 45%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Temozolomide rechallenge is a common, safe, and effective second-line option for patients with MGMT-methylated, IDH wildtype GBM following first-line lomustine\/temozolomide therapy. These findings support its consideration as a salvage therapy in appropriate clinical scenarios.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/noajnl\/vdaf084","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T08:22:16Z","timestamp":1745828536000},"source":"Crossref","is-referenced-by-count":4,"title":["Second-line temozolomide in first recurrent MGMT-methylated glioblastoma after lomustine\/temozolomide: Efficacy and safety"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2919-8622","authenticated-orcid":false,"given":"Thomas","family":"Zeyen","sequence":"first","affiliation":[{"name":"Department of Neurooncology, Center for Neurology and Center for Integrated Oncology (CIO), University Hospital Bonn , Bonn ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Treiber","sequence":"additional","affiliation":[{"name":"Department of Neurooncology, Center for Neurology and Center for Integrated Oncology (CIO), University Hospital Bonn , Bonn ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6025-7479","authenticated-orcid":false,"given":"Matthias","family":"Schneider","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital Bonn , Bonn ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5710-6557","authenticated-orcid":false,"given":"Anna-Laura","family":"Potthoff","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital Bonn , Bonn ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Schaub","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum , Bochum ,","place":["Germany"]},{"name":"Department of Neurooncology, Center for Neurology and Center for Integrated Oncology (CIO), University Hospital Bonn , Bonn ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Roever","sequence":"additional","affiliation":[{"name":"Department of Neurooncology, Center for Neurology and Center for Integrated Oncology (CIO), University Hospital Bonn , Bonn ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian P","family":"Layer","sequence":"additional","affiliation":[{"name":"Institute of Experimental Oncology, University Hospital Bonn , Bonn ,","place":["Germany"]},{"name":"Department of Radiotherapy and Radiation Oncology, University Hospital Bonn , Bonn ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Gkika","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, University Hospital Bonn , Bonn ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Vatter","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital Bonn , Bonn ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Paech","sequence":"additional","affiliation":[{"name":"Department of Radiology, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Neuroradiology, University Hospital Bonn , Bonn ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Radbruch","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, University Hospital Bonn , Bonn ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Schaefer","sequence":"additional","affiliation":[{"name":"Department of Neurooncology, Center for Neurology and Center for Integrated Oncology (CIO), University Hospital Bonn , Bonn ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Herrlinger","sequence":"additional","affiliation":[{"name":"Department of Neurooncology, Center for Neurology and Center for Integrated Oncology (CIO), University Hospital Bonn , Bonn ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5818-5392","authenticated-orcid":false,"given":"Johannes","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Vascular Neurology, Center for Neurology, University Hospital Bonn , Bonn ,","place":["Germany"]},{"name":"Department of Neurooncology, Center for Neurology and Center for Integrated Oncology (CIO), University Hospital Bonn , Bonn ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"issue":"10","key":"2025062609224254500_CIT0001","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1158\/1055-9965.EPI-14-0275","article-title":"Epidemiologic and molecular prognostic review of glioblastoma","volume":"23","author":"Thakkar","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"8","key":"2025062609224254500_CIT0002","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro Oncol"},{"issue":"10","key":"2025062609224254500_CIT0003","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"10","key":"2025062609224254500_CIT0004","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med."},{"issue":"23","key":"2025062609224254500_CIT0005","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial [published correction appears in JAMA","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA."},{"issue":"10172","key":"2025062609224254500_CIT0006","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet."},{"issue":"3","key":"2025062609224254500_CIT0007","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood [published correction appears in Nat Rev Clin Oncol","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol."},{"key":"2025062609224254500_CIT0008","doi-asserted-by":"crossref","first-page":"102029","DOI":"10.1016\/j.ctrv.2020.102029","article-title":"How did lomustine become standard of care in recurrent glioblastoma","volume":"87","author":"Weller","year":"2020","journal-title":"Cancer Treat Rev."},{"issue":"1","key":"2025062609224254500_CIT0009","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial","volume":"23","author":"Wen","year":"2022","journal-title":"Lancet Oncol."},{"issue":"8","key":"2025062609224254500_CIT0010","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med."},{"issue":"8","key":"2025062609224254500_CIT0011","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med."},{"issue":"20","key":"2025062609224254500_CIT0012","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N Engl J Med."},{"issue":"9","key":"2025062609224254500_CIT0013","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-14-2737","article-title":"MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR Trial","volume":"21","author":"Weller","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"12","key":"2025062609224254500_CIT0014","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.2009.26.5520","article-title":"Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study","volume":"28","author":"Perry","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025062609224254500_CIT0015","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","article-title":"Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"20","author":"Lombardi","year":"2019","journal-title":"Lancet Oncol."},{"key":"2025062609224254500_CIT0016","author":"Drug Information for Lomustine","journal-title":"Drug information for lomustine from BC cancer"},{"issue":"33","key":"2025062609224254500_CIT0017","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults","volume":"41","author":"Wen","year":"2023","journal-title":"J Clin Oncol."},{"issue":"35","key":"2025062609224254500_CIT0018","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1200\/JCO.2009.23.6497","article-title":"NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide [published correction appears in J Clin Oncol. 2010 Feb 1;28(4):708]","volume":"27","author":"Wick","year":"2009","journal-title":"J Clin Oncol."},{"issue":"1","key":"2025062609224254500_CIT0019","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE\u2014Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. CTCAE versi\u00f3n 5.0. Evaluaci\u00f3n de la gravedad de los eventos adversos dermatol\u00f3gicos de las terapias antineopl\u00e1sicas","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"57","key":"2025062609224254500_CIT0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13063-021-05977-0","article-title":"Phase I\/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy\u2014the MecMeth\/NOA-24 trial","volume":"23","author":"Zeyen","year":"2022","journal-title":"Trials"},{"issue":"6","key":"2025062609224254500_CIT0021","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/neuonc\/noad002","article-title":"Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival","volume":"25","author":"Ellingson","year":"2023","journal-title":"Neuro Oncol"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdaf084\/63017943\/vdaf084.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf084\/63017943\/vdaf084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf084\/63017943\/vdaf084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T13:22:52Z","timestamp":1750944172000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdaf084\/8120832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdaf084","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]},"article-number":"vdaf084"}}